- Home
- CRT vs BCAB Comparison
CRT vs BCAB Comparison
Compare CRT & BCAB Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- CRT
- BCAB
- Stock Information
- Founded
- CRT 1991
- BCAB 2007
- Country
- CRT United States
- BCAB United States
- Employees
- CRT N/A
- BCAB N/A
- Industry
- CRT Oil & Gas Production
- BCAB Medicinal Chemicals and Botanical Products
- Sector
- CRT Energy
- BCAB Health Care
- Exchange
- CRT Nasdaq
- BCAB Nasdaq
- Market Cap
- CRT 65.1M
- BCAB 22.3M
- IPO Year
- CRT 1992
- BCAB 2020
- Fundamental
- Price
- CRT $9.70
- BCAB $0.38
- Analyst Decision
- CRT
- BCAB Buy
- Analyst Count
- CRT 0
- BCAB 2
- Target Price
- CRT N/A
- BCAB $1.00
- AVG Volume (30 Days)
- CRT 22.2K
- BCAB 491.4K
- Earning Date
- CRT 01-01-0001
- BCAB 08-07-2025
- Dividend Yield
- CRT 9.19%
- BCAB N/A
- EPS Growth
- CRT N/A
- BCAB N/A
- EPS
- CRT 0.99
- BCAB N/A
- Revenue
- CRT $6,834,116.00
- BCAB $11,000,000.00
- Revenue This Year
- CRT N/A
- BCAB N/A
- Revenue Next Year
- CRT N/A
- BCAB N/A
- P/E Ratio
- CRT $9.81
- BCAB N/A
- Revenue Growth
- CRT N/A
- BCAB N/A
- 52 Week Low
- CRT $8.88
- BCAB $0.24
- 52 Week High
- CRT $13.31
- BCAB $2.53
- Technical
- Relative Strength Index (RSI)
- CRT 41.51
- BCAB 42.25
- Support Level
- CRT $9.74
- BCAB $0.36
- Resistance Level
- CRT $9.99
- BCAB $0.43
- Average True Range (ATR)
- CRT 0.18
- BCAB 0.04
- MACD
- CRT 0.00
- BCAB -0.00
- Stochastic Oscillator
- CRT 8.11
- BCAB 16.10
About CRT Cross Timbers Royalty Trust
Cross Timbers Royalty Trust is a United States-based trust. The net profits interests are derived from producing royalty, overriding royalty interests, and working interest properties. The underlying properties of the trust include producing properties in Texas, Oklahoma, and New Mexico.
About BCAB BioAtla Inc.
BioAtla Inc is a clinical-stage biopharmaceutical company. The company is engaged in the development of a novel class of specific and selective antibody-based therapeutics for the treatment of solid tumor cancer. Its pipeline products comprise mecbotamab vedotin (BA3011), ozuriftamab vedotin (BA3021), and evalstotug (BA3071), and its Phase 1 clinical trial of BA3182 (CAB-EpCAM x CAB-CD3) and Bispecific antibody programs.